(Total Views: 647)
Posted On: 03/05/2021 9:40:53 PM
Post# of 153898
Great point calstang. Mortality was the endpoint, hense the data release.
I wonder how the progression from severe to critical compares between treatment arm and placebo.
We now KNOW that we substantially reduce mortality. Clinically significant.
We now KNOW that we reduced time to recovery over SOC. Statistically significant.
We now KNOW that in the moderate group the NEWS2 score is statistically significant.
What if we find out that LL reduced progression from severe to critical by a meaningful amount. Would that not paint an entire picture of the overall efficacy of LL?
As Respert has said, "even a cross-eyed person can connect those dots."
I wonder how the progression from severe to critical compares between treatment arm and placebo.
We now KNOW that we substantially reduce mortality. Clinically significant.
We now KNOW that we reduced time to recovery over SOC. Statistically significant.
We now KNOW that in the moderate group the NEWS2 score is statistically significant.
What if we find out that LL reduced progression from severe to critical by a meaningful amount. Would that not paint an entire picture of the overall efficacy of LL?
As Respert has said, "even a cross-eyed person can connect those dots."
(8)
(0)
